Corcept Therapeutics Incorporated Stock Net Income
| CORT Stock | USD 57.54 1.62 2.90% |
Corcept Therapeutics Incorporated fundamentals help investors to digest information that contributes to Corcept Therapeutics' financial success or failures. It also enables traders to predict the movement of Corcept Stock. The fundamental analysis module provides a way to measure Corcept Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corcept Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 106.1 M | 111.4 M | |
| Net Income From Continuing Ops | 106.1 M | 111.4 M | |
| Net Income Applicable To Common Shares | 116.5 M | 122.3 M | |
| Net Income Per Share | 1.02 | 1.08 | |
| Net Income Per E B T | 0.85 | 1.03 |
Corcept | Net Income |
Corcept Therapeutics Incorporated Company Net Income Analysis
Corcept Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Corcept Therapeutics Net Income | 106.14 M |
Most of Corcept Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corcept Therapeutics Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Corcept Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Corcept Therapeutics is extremely important. It helps to project a fair market value of Corcept Stock properly, considering its historical fundamentals such as Net Income. Since Corcept Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corcept Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corcept Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Corcept Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Corcept Therapeutics Incorporated reported net income of 106.14 M. This is 68.9% lower than that of the Pharmaceuticals sector and 51.53% higher than that of the Health Care industry. The net income for all United States stocks is 81.41% higher than that of the company.
Corcept Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corcept Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics of similar companies.Corcept Therapeutics is currently under evaluation in net income category among its peers.
Corcept Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corcept Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corcept Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Corcept Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Corcept Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Corcept Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corcept Therapeutics' value.| Shares | Btim Corp | 2024-09-30 | 1.5 M | Arrowstreet Capital Limited Partnership | 2024-06-30 | 1.5 M | Fmr Inc | 2024-09-30 | 1.4 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | Northern Trust Corp | 2024-09-30 | 921.4 K | Norges Bank | 2024-06-30 | 822.1 K | D. E. Shaw & Co Lp | 2024-09-30 | 788.1 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 716.1 K | Blackrock Inc | 2024-06-30 | 16.5 M | Vanguard Group Inc | 2024-09-30 | 10 M |
Corcept Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 5.66 B | ||||
| Shares Outstanding | 104.78 M | ||||
| Shares Owned By Insiders | 11.50 % | ||||
| Shares Owned By Institutions | 85.50 % | ||||
| Number Of Shares Shorted | 18.8 M | ||||
| Price To Earning | 30.07 X | ||||
| Price To Book | 9.44 X | ||||
| Price To Sales | 9.59 X | ||||
| Revenue | 482.38 M | ||||
| Gross Profit | 396.47 M | ||||
| EBITDA | 108.32 M | ||||
| Net Income | 106.14 M | ||||
| Cash And Equivalents | 370.09 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 151 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.54 X | ||||
| Book Value Per Share | 6.10 X | ||||
| Cash Flow From Operations | 127.04 M | ||||
| Short Ratio | 17.04 X | ||||
| Earnings Per Share | 1.26 X | ||||
| Price To Earnings To Growth | 0.61 X | ||||
| Target Price | 74.9 | ||||
| Number Of Employees | 352 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 6.03 B | ||||
| Total Asset | 621.52 M | ||||
| Retained Earnings | 402.53 M | ||||
| Working Capital | 354.13 M | ||||
| Current Asset | 48.98 M | ||||
| Current Liabilities | 20.88 M | ||||
| Net Asset | 621.52 M |
About Corcept Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corcept Therapeutics Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.